Instrument Inactif

Communiqués BioRestorative Therapies, Inc. Other OTC

Actions

BRTX

US0906554086

Recherche biotechnologique et médicale

Communiqués

25/06	BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform	AQ
18/06	BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth	AQ
27/05	Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)	AQ
26/05	BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data	AQ
13/05	BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals	AQ
07/05	BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease	AQ
30/04	BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform	AQ
24/04	BioRestorative Therapies : Investor Presentation	PU
21/04	BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform	AQ
07/04	BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform	AQ
30/03	BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease	AQ
19/03	BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease	AQ
05/03	BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026	AQ
04/03	BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy	AQ
24/02	BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs	AQ
14/02	BioRestorative Announces Closing of $5.0 Million Public Offering	AQ
12/02	BioRestorative Announces Pricing of $5.0 Million Public Offering	AQ
11/02	BioRestorative Announces Positive Outcome from Type B Meeting with FDA	AQ
10/02	BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease	AQ
17/11	BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease	AQ
12/11	BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
05/11	BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025	AQ
27/10/25	BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market	AQ
22/10/25	BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio	AQ
15/10/25	BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit	AQ